## Is Immitra Bio's CHF 2.4M Pre-Seed Enough to Advance In-Vivo Gene Editing for Blood Disorders?

CHF 2.4 million (€2.6 million) is a modest pre-seed — but the scientific lineage behind Immitra Bio, a 2025 ETH Zurich spinout, gives this round more signal than the headline number suggests. Founded from the laboratory of ETH Zurich genome-editing researcher Jacob Corn, Immitra is developing an in-vivo gene editing platform that aims to bypass the complex, costly manufacturing process that defines current [cell therapy](https://synbiointel.com/glossary/cell-therapy) approaches. Instead of extracting, editing, and reinfusing a patient's cells, Immitra's approach would deliver gene editing directly inside the body via an off-the-shelf injection. The initial disease focus is an inherited anemia — the specific indication has not been disclosed publicly.

The round comprised CHF 2.25 million from investors and CHF 150,000 in non-dilutive funding. Backbone Ventures led, with OCCIDENT as co-lead. Additional participants included Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation, and private investors. Most proceeds will fund preclinical proof-of-concept studies for lead program IB-003, described by Immitra as a potential one-time treatment for an inherited anemia.

The company has not disclosed IB-003's molecular target, specific disease indication, editing mechanism, or development timeline — significant omissions for any investor conducting technical diligence.

---

## The Scientific Backstory: From Ariya Bio to Immitra

Immitra's origins trace to Ariya Bio, an earlier ETH Zurich project that investigated [CRISPR](https://synbiointel.com/glossary/crispr-cas9)-based reactivation of fetal hemoglobin as a therapeutic strategy for beta-hemoglobin disorders — a mechanism that has attracted substantial industry attention, with companies like Beam Therapeutics and Editas Medicine pursuing similar paths through [base editing](https://synbiointel.com/glossary/base-editing) and nuclease-based approaches. ETH Foundation states that Ariya Bio continued as Immitra in 2025, but Immitra has not confirmed whether IB-003 uses the same fetal hemoglobin reactivation mechanism. That ambiguity is notable: it means external observers cannot yet assess whether IB-003 represents an incremental refinement of known CRISPR-hemoglobin science or a genuinely distinct editing strategy.

What Immitra has stated is that its platform is designed to be mutation agnostic — meaning a single product could treat patients with the same disease regardless of which specific underlying mutation they carry. For inherited anemias like beta-thalassemia or sickle cell disease, where hundreds of causative mutations are documented, mutation agnosticism is a meaningful commercial differentiator. It eliminates the need for patient stratification by genotype and simplifies regulatory strategy.

---

## In-Vivo vs. Ex-Vivo: Why the Distinction Matters Commercially

The current gold-standard gene-edited cell therapies — including approved sickle cell treatments — require leukapheresis, ex-vivo cell engineering under GMP conditions, and patient lymphodepletion before reinfusion. The manufacturing cost and logistical complexity of this process have been primary targets of criticism; treatment costs in the hundreds of thousands of dollars per patient reflect this burden. An in-vivo approach that achieves equivalent editing efficiency without ex-vivo handling would compress the cost structure substantially, provided delivery and specificity challenges can be solved.

This is precisely where the skepticism must be applied. In-vivo delivery of editing machinery to hematopoietic stem cells — the relevant target for inherited blood disorders — remains one of the harder unsolved problems in the field. [AAV](https://synbiointel.com/glossary/aav) vectors have limited cargo capacity for larger editing systems and face well-documented immunogenicity concerns. Lipid nanoparticles have demonstrated liver tropism effectively but achieving bone marrow or HSC-specific delivery at therapeutic levels in vivo has proven difficult. Immitra has not disclosed its delivery modality. Until preclinical data is public, the "off-the-shelf injection" framing should be read as a design goal rather than a validated capability.

---

## What This Signals for European In-Vivo Gene Editing

Immitra enters a competitive field where several well-capitalized players — including Graphite Bio (prior to its pivot), Vor Biopharma, and others — have pursued in-vivo or next-generation HSC editing strategies with substantially larger funding bases. At the European level, however, ETH Zurich's gene editing ecosystem has produced credible science, and Backbone Ventures' participation — alongside the Swiss innovation funding infrastructure of Venture Kick and Zürcher Kantonalbank — represents a geographically coherent early-stage syndicate for a preclinical platform.

The round's size suggests Immitra's near-term objective is a single preclinical proof-of-concept dataset for IB-003 — enough to anchor a seed or Series A with in-vivo efficacy data. Whether CHF 2.4 million is sufficient to reach that milestone depends entirely on the editing system's complexity and the animal models required, neither of which has been disclosed.

For the broader industry, Immitra's emergence from the Jacob Corn lab adds another data point to the thesis that academic gene editing groups are increasingly spinning out with specific therapeutic programs rather than platform-only concepts — a maturation of the ETH Zurich–to–startup pipeline that investors in European deeptech should note.

---

## Key Takeaways

- **CHF 2.4M pre-seed** (CHF 2.25M investor capital + CHF 150K non-dilutive) closed July 2026; Backbone Ventures led, OCCIDENT co-led.
- **Immitra Bio** is a 2025 ETH Zurich spinout from the Jacob Corn genome-editing laboratory, with roots in the earlier Ariya Bio fetal hemoglobin project.
- **IB-003** targets an undisclosed inherited anemia; Immitra describes it as a potential one-time treatment and claims mutation-agnostic design.
- **In-vivo delivery to hematopoietic stem cells** remains the field's key unsolved problem — Immitra has not disclosed its delivery modality, editing mechanism, or HSC tropism data.
- **Preclinical proof-of-concept** is the stated use of proceeds; no clinical timeline has been provided.
- The round's size implies a single-milestone preclinical strategy before a larger raise; investor patience and milestone clarity will be critical.

---

## Frequently Asked Questions

**What is Immitra Bio and who founded it?**
Immitra Bio is a Swiss biotech founded in 2025 as a spinout from ETH Zurich, originating in the laboratory of genome-editing researcher Jacob Corn. It grew from an earlier ETH project called Ariya Bio, which investigated CRISPR-based therapeutic strategies for beta-hemoglobin disorders.

**How much has Immitra Bio raised and from whom?**
Immitra closed a CHF 2.4 million (approximately €2.6 million) pre-seed round comprising CHF 2.25 million in investor capital and CHF 150,000 in non-dilutive funding. Backbone Ventures led the round, with OCCIDENT as co-lead; additional participants included Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, and ETH Foundation.

**What does "mutation agnostic" mean for gene editing therapies?**
A mutation-agnostic therapy is designed to treat patients with the same disease regardless of which specific genetic variant caused it. For inherited blood disorders where hundreds of different mutations can cause the same clinical phenotype, this approach avoids the need to develop separate products for patient subgroups and simplifies regulatory strategy.

**What is IB-003 and what disease does it target?**
IB-003 is Immitra's lead program, described as a potential one-time in-vivo gene editing treatment for an inherited anemia. The company has not disclosed the specific disease, molecular target, editing mechanism, or development timeline.

**Why is in-vivo gene editing for blood disorders technically challenging?**
Blood disorders like sickle cell disease and beta-thalassemia require editing of hematopoietic stem cells (HSCs), which reside primarily in the bone marrow. Delivering gene editing machinery specifically to HSCs in vivo — at sufficient efficiency and with acceptable off-target profiles — remains an unsolved delivery problem. Current approved therapies use ex-vivo editing precisely because in-vivo HSC targeting at therapeutic levels has not been reliably demonstrated in humans.